Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax

Am J Hematol. 2023 Apr;98(4):E80-E83. doi: 10.1002/ajh.26846. Epub 2023 Feb 9.
No abstract available

Publication types

  • Multicenter Study
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Azacitidine / adverse effects
  • Bridged Bicyclo Compounds, Heterocyclic / adverse effects
  • Humans
  • Leukemia, Myeloid, Acute* / etiology
  • Prospective Studies

Substances

  • venetoclax
  • Azacitidine
  • Bridged Bicyclo Compounds, Heterocyclic